No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ABT240628P107000
- 2.85
- +0.37+14.92%
15min DelayClose Jun 28 16:00 ET
2.86High2.85Low
2.86Open2.48Pre Close3 Volume17 Open Interest107.00Strike Price856.00Turnover0.00%IV-0.23%PremiumJun 28, 2024Expiry Date3.09Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma33.63Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
Did Your Heart Skip a Beat? Your Wearable Knows. -- Barrons.com
By Bill Alpert The day is approaching when your wristwatch may send you to the hospital. The first portable electrocardiograph was an 85-pound backpack. Today, a 10-gram patch stuck on your chest ca
Express News | FDA Says Abbott Medical Issues Correction For HeartMate LVAS System Monitor Due To Screen Issues That Could Cause Unintentional Pump Stop
Express News | FDA: Abbott Heartmate Lvas System Monitor Recall Involves Correcting Devices & Does Not Involve Removing Them From Where They Are Used or Sold
Express News | FDA: There Have Been 14 Reported Injuries, No Reports of Death Related to Recall
Express News | FDA: Abbott Medical Issues Correction for Heartmate Lvas System Monitor Due to Screen Issues That May Cause Unintentional Pump Stop
Comments
Morning Movers
Gapping up
$United Airlines(UAL.US$ stock rose 5.2% after the carrier forecast stronger-than-expected earnings in the current quarter and reported a narrower-than-expected loss in the first quarter, buoyed by robust demand for travel.
$Abbott Laboratories(ABT.US$ stock increased by 1.6% after the company surpassed quarterly profit expectations and raised the lower end of its earnings forecast, with strong dem...
Gapping up
$United Airlines(UAL.US$ stock rose 5.2% after the carrier forecast stronger-than-expected earnings in the current quarter and reported a narrower-than-expected loss in the first quarter, buoyed by robust demand for travel.
$Abbott Laboratories(ABT.US$ stock increased by 1.6% after the company surpassed quarterly profit expectations and raised the lower end of its earnings forecast, with strong dem...
30
$Abbott Laboratories(ABT.US$
Introduction
On April 17th, before the US stock market opened, Abbott (NYSE: ABT) will hold a conference call to announce its financial results for the first quarter of 2024. As a global leader in healthcare, Abbott's performance has been steadily improving in recent years, especially benefiting from the COVID-19 pandemic. According to Bloomberg data, the follow...
Introduction
On April 17th, before the US stock market opened, Abbott (NYSE: ABT) will hold a conference call to announce its financial results for the first quarter of 2024. As a global leader in healthcare, Abbott's performance has been steadily improving in recent years, especially benefiting from the COVID-19 pandemic. According to Bloomberg data, the follow...
1
$Abbott Laboratories(ABT.US$ Hmmm. As usual, red again
Insiders selling shares with no recorded purchases over the last year could worry investors. Despite high insider ownership, recent selling activity suggests insiders don't see shares as a bargain.
The 4- and 5-star rated Dividend Aristocrats for 2024 include Abbott Laboratories, AbbVie Inc., Air Products & Chemicals, and others such as Coca-Cola Co., McDonald's Corp., Walmart Inc., and West Pharmaceuticals.
1
Read more